Ergoteles’s Heron Therapeutics HRTX Stock Holding History

Ergoteles’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-119,967	Closed	-$300K	–	1464
2022 Q4	$300K	Sell	119,967 -13,985	-10%	-$45.1K	0.01%	909
2022 Q3	$565K	Buy	+133,952	New	+$524K	0.02%	710
2022 Q1	–	Sell	-100,229	Closed	-$915K	–	1394
2021 Q4	$915K	Buy	100,229 +70,344	+235%	+$718K	0.04%	439
2021 Q3	$319K	Buy	+29,885	New	+$364K	0.01%	772

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ergoteles's HRTX Position: Q1 2023 in Review

Ergoteles sold out of Heron Therapeutics (HRTX) in Q1 2023, closing a stake of 119,967 shares — an estimated $300K sold.

Ergoteles first reported a position in HRTX in Q3 2021 and held it in 4 quarters. The position peaked at $915K in Q4 2021. 162 funds tracked by Wall St. Rank hold HRTX as of Q1 2023.

Ergoteles reported no remaining Heron Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 119,967 Heron Therapeutics shares in Q1 2023, an estimated $300K.
Ergoteles first reported a position in Heron Therapeutics in Q3 2021 and held it in 4 quarters.
Ergoteles's Heron Therapeutics position peaked at $915K in Q4 2021.
162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.